• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大环内酯类药物抑制高毒力且促进固有免疫易感性的荚膜形成。

Macrolides Inhibit Capsule Formation of Highly Virulent and Promote Innate Immune Susceptibility.

机构信息

Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan

Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.

出版信息

Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.02364-18. Print 2019 Jun.

DOI:10.1128/AAC.02364-18
PMID:30936099
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6535557/
Abstract

is a fungal pathogen, endemic in tropical and subtropical regions, the west coast of Canada, and the United States, that causes a potentially fatal infection in otherwise healthy individuals. Because the cryptococcal polysaccharide capsule is a leading virulence factor due to its resistance against innate immunity, the inhibition of capsule formation may be a promising new therapeutic strategy for Macrolides have numerous nonantibiotic effects, including immunomodulation of mammalian cells and suppression of bacterial (but not fungal) pathogenicity. Thus, we hypothesized that a macrolide would inhibit cryptococcal capsule formation and improve the host immune response. Coincubation with clarithromycin (CAM) and azithromycin significantly reduced the capsule thickness and the amount of capsular polysaccharide of both and CAM-treated cells were significantly more susceptible to HO oxidative stress and opsonophagocytic killing by murine neutrophils. In addition, more cells were phagocytosed by murine macrophages, resulting in increased production of tumor necrosis factor alpha (TNF-α) by CAM exposure. After CAM exposure, dephosphorylation of Hog1, one of the mitogen-activated protein kinase (MAPK) signaling pathways of , was observed in Western blot analysis. In addition, CAM exposure significantly reduced the mRNA expression of and (such mRNA expression is associated with cell wall integrity and melanin production). These results suggest that CAM may aid in inhibiting capsular formation via the MAPK signaling pathway and by suppressing virulent genes; thus, it may be a useful adjunctive agent for treatment of refractory infection.

摘要

荚膜组织胞浆菌是一种真菌病原体,存在于热带和亚热带地区、加拿大西海岸和美国,它会导致原本健康的个体患上潜在致命的感染。由于 cryptococcal 多糖荚膜是一种主要的毒力因子,因为它能抵抗先天免疫,因此抑制荚膜形成可能是治疗 大环内酯类药物具有许多非抗生素作用,包括对哺乳动物细胞的免疫调节和抑制细菌(但不是真菌)的致病性。因此,我们假设大环内酯类药物会抑制 cryptococcal 荚膜形成并改善宿主免疫反应。与克拉霉素(CAM)和阿奇霉素共同孵育可显著降低 和 的荚膜厚度和荚膜多糖含量。CAM 处理的 细胞对 HO 氧化应激和鼠中性粒细胞的调理吞噬杀伤作用明显更敏感。此外,更多的 细胞被鼠巨噬细胞吞噬,导致 CAM 暴露后 TNF-α 的产生增加。CAM 暴露后,Western blot 分析观察到 MAPK 信号通路中的一种丝裂原活化蛋白激酶(MAPK)途径的 Hog1 去磷酸化。此外,CAM 暴露还显著降低了 和 (与细胞壁完整性和黑色素产生相关的 mRNA 表达)的 mRNA 表达。这些结果表明,CAM 可能通过 MAPK 信号通路和抑制毒力基因来帮助抑制荚膜形成;因此,它可能是治疗难治性 感染的有用辅助剂。

相似文献

1
Macrolides Inhibit Capsule Formation of Highly Virulent and Promote Innate Immune Susceptibility.大环内酯类药物抑制高毒力且促进固有免疫易感性的荚膜形成。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.02364-18. Print 2019 Jun.
2
Transcriptional Heterogeneity of VGII Compared with Non-VGII Lineages Underpins Key Pathogenicity Pathways.与非 VGII 谱系相比,VGII 的转录异质性为关键致病途径提供了基础。
mSphere. 2018 Oct 24;3(5):e00445-18. doi: 10.1128/mSphere.00445-18.
3
A Predicted Mannoprotein Participates in Capsular Structure.一种预测的甘露糖蛋白参与荚膜结构。
mSphere. 2018 Apr 25;3(2). doi: 10.1128/mSphere.00023-18.
4
Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.高毒力加氏隐球菌通过改变荚膜葡糖醛酸木聚糖结构逃避天然免疫反应
Front Cell Infect Microbiol. 2016 Jan 6;5:101. doi: 10.3389/fcimb.2015.00101. eCollection 2015.
5
Cryptococcus gattii Capsule Blocks Surface Recognition Required for Dendritic Cell Maturation Independent of Internalization and Antigen Processing.新型隐球菌荚膜可阻断树突状细胞成熟所需的表面识别,且与内化作用和抗原处理无关。
J Immunol. 2016 Feb 1;196(3):1259-71. doi: 10.4049/jimmunol.1501089. Epub 2016 Jan 6.
6
A Novel Protocol for the Isolation of Fungal Extracellular Vesicles Reveals the Participation of a Putative Scramblase in Polysaccharide Export and Capsule Construction in .一种新型真菌细胞外囊泡分离方案揭示了一种假定的翻转酶在多糖外排和 荚膜构建中的参与作用。
mSphere. 2019 Mar 20;4(2):e00080-19. doi: 10.1128/mSphere.00080-19.
7
Pulmonary Iron Limitation Induced by Exogenous Type I IFN Protects Mice from Cryptococcus gattii Independently of T Cells.外源性 I 型 IFN 诱导的肺部铁限制可独立于 T 细胞保护小鼠免受新型隐球菌感染。
mBio. 2019 Jun 18;10(3):e00799-19. doi: 10.1128/mBio.00799-19.
8
Chitosan Biosynthesis and Virulence in the Human Fungal Pathogen Cryptococcus gattii.壳聚糖生物合成与人类真菌病原体荚膜组织胞浆菌的毒力。
mSphere. 2019 Oct 9;4(5):e00644-19. doi: 10.1128/mSphere.00644-19.
9
Cryptococcus gattii virulence composite: candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains.荚膜组织胞浆菌毒力复合群:高毒力和低毒力温哥华岛暴发株的芯片分析揭示的候选基因。
PLoS One. 2011 Jan 13;6(1):e16076. doi: 10.1371/journal.pone.0016076.
10
Interferon-γ promotes phagocytosis of Cryptococcus neoformans but not Cryptococcus gattii by murine macrophages.γ干扰素可促进小鼠巨噬细胞对新型隐球菌的吞噬作用,但对格特隐球菌无此作用。
J Infect Chemother. 2015 Dec;21(12):831-6. doi: 10.1016/j.jiac.2015.08.001. Epub 2015 Oct 23.

引用本文的文献

1
Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.新一代抗真菌药物:作用机制、疗效及临床前景。
Acta Pharm Sin B. 2025 Aug;15(8):3852-3887. doi: 10.1016/j.apsb.2025.06.013. Epub 2025 Jun 23.
2
Diagnosis and management of cryptococcal meningitis in HIV-infected adults.HIV 感染者隐球菌性脑膜炎的诊断与治疗。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0015622. doi: 10.1128/cmr.00156-22. Epub 2023 Nov 28.
3
Combating increased antifungal drug resistance in , what should we do in the future?未来我们应该如何应对 的抗真菌药物耐药性增加问题?
Acta Biochim Biophys Sin (Shanghai). 2023 Feb 22;55(4):540-547. doi: 10.3724/abbs.2023011.
4
Treatment strategies for cryptococcal infection: challenges, advances and future outlook.隐球菌感染的治疗策略:挑战、进展与未来展望。
Nat Rev Microbiol. 2021 Jul;19(7):454-466. doi: 10.1038/s41579-021-00511-0. Epub 2021 Feb 8.

本文引用的文献

1
Innate Immunity against Cryptococcus, from Recognition to Elimination.针对新型隐球菌的天然免疫:从识别到清除
J Fungi (Basel). 2018 Mar 7;4(1):33. doi: 10.3390/jof4010033.
2
Physiological Differences in Cryptococcus neoformans Strains versus and Their Effects on Antifungal Susceptibility.新型隐球菌菌株的生理差异及其对抗真菌药敏性的影响
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02108-16. Print 2017 Mar.
3
Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.高毒力加氏隐球菌通过改变荚膜葡糖醛酸木聚糖结构逃避天然免疫反应
Front Cell Infect Microbiol. 2016 Jan 6;5:101. doi: 10.3389/fcimb.2015.00101. eCollection 2015.
4
Interferon-γ promotes phagocytosis of Cryptococcus neoformans but not Cryptococcus gattii by murine macrophages.γ干扰素可促进小鼠巨噬细胞对新型隐球菌的吞噬作用,但对格特隐球菌无此作用。
J Infect Chemother. 2015 Dec;21(12):831-6. doi: 10.1016/j.jiac.2015.08.001. Epub 2015 Oct 23.
5
Macrolides Promote CCL2-Mediated Macrophage Recruitment and Clearance of Nasopharyngeal Pneumococcal Colonization in Mice.大环内酯类促进 CCL2 介导体细胞招募和清除鼻咽部肺炎链球菌定植的作用。
J Infect Dis. 2015 Oct 1;212(7):1150-9. doi: 10.1093/infdis/jiv157. Epub 2015 Mar 12.
6
Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia.不列颠哥伦比亚省新型隐球菌感染患者的纵向临床发现和结局。
Clin Infect Dis. 2015 May 1;60(9):1368-76. doi: 10.1093/cid/civ041. Epub 2015 Jan 28.
7
The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.活性氧的产生是两性霉素B抗致病性酵母的一种普遍作用机制,并且有助于该药物的杀菌效果。
Antimicrob Agents Chemother. 2014 Nov;58(11):6627-38. doi: 10.1128/AAC.03570-14. Epub 2014 Aug 25.
8
The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model.在小鼠模型中,新型隐球菌的主要靶器官与格特隐球菌不同。
mBio. 2012 May 8;3(3). doi: 10.1128/mBio.00103-12. Print 2012.
9
Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.隐球菌中三唑类药物的流行病学截断值:分子类型与体外药敏的相关性。
Diagn Microbiol Infect Dis. 2012 Jun;73(2):144-8. doi: 10.1016/j.diagmicrobio.2012.02.018. Epub 2012 Apr 10.
10
Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains.胶囊大小对体外抗真菌药物活性的影响对临床新型隐球菌 var. grubii 株。
J Med Microbiol. 2012 Mar;61(Pt 3):384-388. doi: 10.1099/jmm.0.036152-0. Epub 2011 Nov 10.